Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.
The unexpected approval of Vyondys 53 followed an FDA power struggle, and turned on a vague commitment from Sarepta, it has emerged.
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.